Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects

Journal of Clinical Pharmacology

Volumn 45, Issue 8, 2005, Pages 941-946

  Kim, Kyoung Ah ^a   Park, Pil Whan ^a   Kim, Hyung Kee ^b   Ha, Jong Myung ^c   Park, Ji Young ^a  

^a Gachon University College of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Silla University   (South Korea)

Author keywords

Cytochrome P450 2C8 (CYP2C8); Drug interaction; Quercetin; Rosiglitazone

Indexed keywords

CYTOCHROME P450 2C8; DRUG METABOLITE; NORROSIGLITAZONE; PLACEBO; QUERCETIN; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC CLEARANCE RATE; QUERCETIN; THIAZOLIDINEDIONES;

EID: 23044511374     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005278407     Document Type: Article

References (40)

1. Middleton E Jr. Effect of plant flavonoids on immune and inflammatory cell function. Adv Exp Med Biol. 1998;439:175-182.
2. Bors W, Heller W, Michel C, Saran M. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Methods Enzymol. 1990;186:343-355.
3. Inal ME, Akgun A, Kahraman A. Radioprotective effects of exogenous glutathione against whole-body gamma-ray irradiation: age-and gender-related changes in malondialdehyde levels, superoxide dismutase and catalase activities in rat liver. Methods Find. Exp Clin Pharmacol. 2002;24:209-212.
4. Laughton MJ, Evans PJ, Moroney MA, Hoult JR, Halliwell B. Inhibition of mammalian 5-lipoxygenase and cyclo-oxygenase by flavonoids and phenolic dietary additives: relationship to antioxidant activity and to iron ion-reducing ability. Biochem Pharmacol. 1991;42:1673-1681.
5. Afanas'ev IB, Dorozhko AI, Brodskii AV, Kostyuk VA, Potapovitch AI. Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. Biochem Pharmacol. 1989;38:1763-1769.
6. Formica JV, Regelson W. Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol. 1995;33:1061-1080.
7. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79:727-747.
8. Kim KA, Park JY, Lee JS, Lim S. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003;26:631-637.
9. Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004;60:575-581.
10. Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J. Drug interactions of paclitaxel metabolism in human liver microsomes. J Chemother. 2003;15:266-274.
11. Balfour JA, Plosker GL. Rosiglitazone. Drugs. 1999;57:921-930.
12. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther. 2000;22:1151-1168.
13. Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos. 2000;28:772-780.
14. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999;48:424-432.
15. Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther. 2004;76:239-249.
16. Park JY, Kim KA, Kang MH, Kim SL, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther. 2004;75:157-162.
17. Park JY, Kim KA, Shin JG, Lee KY. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol. 2004;58:397-402.
18. Vaclavikova R, Horsky S, Simek P, Gut I, Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants, Naunyn Schmiedebergs Arch Pharmacol. 2003;368:200-209.
19. Hollman PC, Katan MB. Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother. 1997;51:305-310.
20. Schwedhelm E, Maas R, Troost R, Boger RH. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet. 2003;42:437-459.
21. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999;54:960-963.
22. Boyle SP, Dobson VL, Duthie SJ, Hinselwood DC, Kyle JA, Collins AR. Bioavailability and efficiency of rutin as an antioxidant: a human supplementation study. Eur J Clin Nutr. 2000;54:774-782.
23. Katske F, Shoskes DA, Sender M, Poliakin R, Gagliano K, Rajfer J. Treatment of interstitial cystitis with a quercetin supplement. Tech Urol 2001;7:44-46.
24. Kim KA, Park JY, Simple and extractionless high-performance liquid chromatographic determination of rosiglitazone in human plasma and application to pharmacokinetics in humans. Biomed Chromatogr. 2004;18;613-615.
25. Choi JS, Jo BW, Kim YC. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm. 2004;57:313-318.
26. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia. 2003;46:1319-1323.
27. Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 2002;30:1352-1356.
28. Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 2002;30:631-635.
29. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry, Drug Metab Dispos. 2001;29:23-29.
30. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA. 1997;94:2031-2035.
31. Kegawa T, Ohtani H, Koyabu N, et al. Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett. 2002;177:89-93.
32. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev. 2004;36:57-104.
33. Choi JS, Choi BC, Choi KE. Effect of quercetin on the pharmacokinetics of oral cyclosporine. Am J Health Syst Pharm. 2004;61:2406-409.
34. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000;130(Suppl):2073S-2085S.
35. Erlund I, Kosonen T, Alfthan G, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol. 2000;56:545-553.
36. Kageyama M, Namiki H, Fukushima H, et al. Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats. Biol Pharm Bull. 2005;28:130-137.
37. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther. 2000;67:335-341.
38. Rashid J, McKinstry C, Renwick AG, Dirnhuber M, Waller DG, George CF. Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol. 1993;36:460-463.
39. Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follath F. In vitro inhibition of midazolam and quinidine metabolism by flavonoids. Eur J Clin Pharmacol. 1995;48:367-371.
40. Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-exprossed cytochrome P450 enzyme calalylic activity. Life Sci. 2002;71:1579-1589.